Huma Secures EU MDR Approval For Medtech Software That Can Be Used In Any Disease
Executive Summary
Huma Therapeutics has secured the first ever EU regulatory approval for a “disease agnostic” class IIb medtech software platform. CEO Dan Vahdat tells Medtech Insight how the product can be configured to monitor patients with any condition.
You may also be interested in...
Huma Granted Class II Clearance By FDA For Its Disease-Agnostic Platform
Huma’s platform is now the only remote patient monitoring platform approved in both the US and Europe that is able to aid clinicians in their work.
Speaking To AstraZeneca And Huma About Digital’s Value For Pharma
AstraZeneca has been working with Huma to develop a series of software-based tools for monitoring patients. Medtech Insight spoke to both companies about the value of these partnerships and the potential challenges.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.